This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Eklira Genuair, aclidi...
Human medicines European public assessment report (EPAR): Giotrif, afatinib, Dat...
Herbal medicinal product: Pilosellae herba cum radiceArray, F: Assessment finalised
Agenda - PDCO agenda of the 25-28 February 2025 meeting
Human medicines European public assessment report (EPAR): Xtandi, enzalutamide, ...
Medicinal products for human use: monthly figures - January 2025
CTIS newsflash - 25 February 2025
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, ...
Human medicines European public assessment report (EPAR): Brimica Genuair, aclid...
Human medicines European public assessment report (EPAR): Eptifibatide Accord, e...
Human medicines European public assessment report (EPAR): Bretaris Genuair, acli...
Human medicines European public assessment report (EPAR): Trumenba, meningococca...
Human medicines European public assessment report (EPAR): Seladelpar Gilead, Sel...
Human medicines European public assessment report (EPAR): Tacforius, tacrolimus,...
Questions and answers for biological medicinal products
Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pre...
Human medicines European public assessment report (EPAR): Carvykti, ciltacabtage...
Herbal medicinal product: Tribuli terrestris herbaArray, D: Draft under discussion
Herbal medicinal product: Prunus avium peduncleArray,Array, D: Draft under discu...
Veterinary medicines European public assessment report (EPAR): Poulvac Procerta ...
Veterinary medicines European public assessment report (EPAR): Icthiovac ERM, in...